The board of Etac has appointed Fredrik Dalborg to be the new CEO. He is currently the CEO of Boule Diagnostics, a blood diagnostics company listed on the Stockholm stock exchange. Prior to this he worked for more than 15 years with Gambro and Terumo BCT where he held various roles including business development, sales as well as product- and business unit management, based out of Sweden, the US, Belgium and Asia. Fredrik Dalborg will assume his new role in January 2020.

”The Board is convinced that Fredrik Dalborg has a strong background to lead Etac in the next phase of growing the company. He has extensive experience from the medtech industry, has worked in a global setting for 20 years based out of Europe as well as the US and Asia and he has solid experience driving growth”, says Nora Larssen, the chair of Etac.

”I am impressed by how Etac systematically has built a position as a strong, global company and I am enthusiastic about the chance to lead a company that develops renowned products for the global mobility and patient handling market. I see great opportunities to together with the rest of the Etac team continue to develop the company and drive the growth journey”, says Fredrik Dalborg.

For more information:
Nora Larssen, chairman of the board
+46 70 665 6585